MA42523A - ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND TO PSMA AND CD3 AND THEIR USES - Google Patents

ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND TO PSMA AND CD3 AND THEIR USES

Info

Publication number
MA42523A
MA42523A MA042523A MA42523A MA42523A MA 42523 A MA42523 A MA 42523A MA 042523 A MA042523 A MA 042523A MA 42523 A MA42523 A MA 42523A MA 42523 A MA42523 A MA 42523A
Authority
MA
Morocco
Prior art keywords
psma
bind
antigen binding
binding molecules
bispecific antigen
Prior art date
Application number
MA042523A
Other languages
French (fr)
Other versions
MA42523B1 (en
Inventor
Alison Crawford
Drew Dudgeon
Lauric Haber
Jessica R Kirshner
Ashique Rafique
Eric Smith
Gavin Thurston
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Priority claimed from PCT/US2016/044732 external-priority patent/WO2017023761A1/en
Publication of MA42523A publication Critical patent/MA42523A/en
Publication of MA42523B1 publication Critical patent/MA42523B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pregnancy & Childbirth (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA42523A 2015-07-31 2016-07-29 Anti-psma antibodies, bispecific antigen-binding molecules which bind psma and cd3 and uses thereof MA42523B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562199823P 2015-07-31 2015-07-31
PCT/US2016/044732 WO2017023761A1 (en) 2015-07-31 2016-07-29 Anti-psma antibodies, bispecific antigen-binding molecules that bind psma and cd3, and uses thereof

Publications (2)

Publication Number Publication Date
MA42523A true MA42523A (en) 2018-06-06
MA42523B1 MA42523B1 (en) 2023-03-31

Family

ID=85793864

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42523A MA42523B1 (en) 2015-07-31 2016-07-29 Anti-psma antibodies, bispecific antigen-binding molecules which bind psma and cd3 and uses thereof

Country Status (1)

Country Link
MA (1) MA42523B1 (en)

Also Published As

Publication number Publication date
MA42523B1 (en) 2023-03-31

Similar Documents

Publication Publication Date Title
MA45712A (en) ANTI-GPRC5D ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND TO GPRC5D AND CD3 AND THEIR USES
MA53750A (en) ANTI-BCMA ANTIBODIES, B-SPECIFIC ANTIGEN BINDING MOLECULES WHICH BIND TO BCMA AND CD3 AND THEIR USES
MA43164A (en) ANTI-IL1RAP ANTIBODIES, BISPECIFIC MOLECULES OF BINDING ANTIGEN BINDING IL1RAP AND CD3 AND THEIR USES
MA46417A (en) ANTI-STEAP2 ANTIBODIES, ANTIBODY-DRUG CONJUGATES, AND BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND TO STEAP2 AND CD3, AND THEIR USES
DK3328888T3 (en) ANTI-PSMA antibodies, bispecific antigen binding molecules that bind PSMA AND and CD3, and uses thereof
MA49457A (en) CD73 BINDING ANTIBODY MOLECULES AND THEIR USES
ECSP17081420A (en) HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
MA52771A (en) ANTI-CD33 ANTIBODIES, ANTI-CD33 / ANTI-CD3 BISPECIFIC ANTIBODIES AND THEIR USES
MA54514A (en) ANTIBODIES BINDING TO CD3
DK3328892T3 (en) BISPECIFIC ANTIBODY CONSTRUCTIONS BINDING EGFRVIII AND CD3
MA42935A (en) OPTIMIZED ANTI-CD3 BISPECIFIC ANTIBODIES AND THEIR USES
UY37083A (en) ANTI-ROR1 ANTIBODIES, ROR1 X CD3 BISPECTIFIC ANTIBODIES AND METHODS FOR USE
MA43186A (en) ANTIBODIES SPECIFICALLY BINDING TO PD-1 AND THEIR USES
DK3328889T3 (en) BISPECIFIC ANTIBODY CONSTRUCTIONS BINDING DLL3 AND CD3
MA42808A (en) IL-8 BINDING ANTIBODIES AND THEIR USES
MA49565A (en) AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND THEIR USES
MA42059A (en) PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) BISPECIFIC BINDING AGENTS AND USES
MA49846A (en) ANTIBODIES THAT BOUND TO EGFR AND CMET
MA44072A (en) ANTIBODIES SPECIFICALLY BINDING TO HLA-DR AND THEIR USES
MA41480A (en) ANTIBODIES BOUND TO CCR6 AND THEIR USES
MA42523A (en) ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND TO PSMA AND CD3 AND THEIR USES
MA39405B1 (en) Bispecific antibodies binding to cd38 and cd3